Biochemical Engineering Special Interest Group
biological engineering professionals
02 February 2016

GSK and Adaptimmune expand collaboration

GlaxoSmithKline has expanded its alliance with Adaptimmune Therapeutics to accelerate its lead clinical cancer programme toward pivotal trials in synovial sarcoma. Under the expanded arrangement, the firms will accelerate the development of NY-ESO therapy into pivotal synovial sarcoma studies and also explore development in myxoid round cell liposarcoma. Additionally, they may initiate up to eight proof-of-principle studies exploring combinations with other therapies, including checkpoint inhibitors. The studies will be conducted by Adaptimmune with GSK effectively funding the pivotal studies and sharing the costs of the combination studies via a success-based milestone structure. Source: Pharmatimes 2/2/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).